-
Cannabis And Crohn's Disease
Friday, August 23, 2019 - 8:52am | 1055Read More...By WeedMaps News' Tina Magrabi, provided exclusively to Benzinga Cannabis. Crohn's disease is an autoimmune disease that causes severe irritation and inflammation in the digestive tract. A form of inflammatory bowel disease (IBD), the condition often develops in young adults...
-
RedHill Earns Long-Awaited Boost On Positive Crohn's Data
Monday, July 30, 2018 - 10:15am | 351Read More...REDHILL BIOPHAR/S ADR (NASDAQ: RDHL) achieved positive top-line results in its Phase 3 study of RHB-104 in Crohn’s disease, according to a Monday press release. What Happened The drug met both primary and secondary endpoints by demonstrating a remission rate superior to that of the placebo...
-
Celgene May Have Lost Positive Sentiment, But Its Growth Thesis Hasn't Gone Anywhere
Friday, October 27, 2017 - 9:21am | 365Read More...William Blair said in a note the double hit on Celgene Corporation (NASDAQ: CELG)'s Inflammation and Immunology franchise may have reversed positive sentiment, but the company's growth thesis and pipeline optionality remains intact. The firm reiterated its Outperform rating on the shares of the...
-
Pipeline Bomb: Analysts Review Celgene's Crohn's Diseases Failure
Friday, October 20, 2017 - 2:14pm | 611Read More...Celgene Corporation (NASDAQ: CELG) stock plummeted 10 percent Friday after the company reported that its testing of GED-0301 for treatment of Crohn’s disease has failed to meet its efficacy targets. A handful of Wall Street analysts weighed in on Celgene stock following the news. Here’s...
-
Exclusive: RedHill Biopharma CEO Talks Steering His Company Through A Year Heavy With Potential Catalysts
Monday, June 5, 2017 - 3:54pm | 1228Read More...If investors were to sum up the year 2017 for specialty drug maker RedHill Biopharma Ltd - ADR (NASDAQ: RDHL) in one phrase, it might be this: “catalyst-rich.” A specialty biopharmaceutical company based in Israel, RedHill has a treasure trove of developing drugs in its pipeline to...
-
Protagonist Therapeutics Spikes Sharply After Agreement With Janssen
Tuesday, May 30, 2017 - 11:12am | 168Read More...Protagonist Therapeutics Inc(NASDAQ: PTGX) shares are trading higher by $3.54 — over 43 percent — at $11.76 in Tuesday's session. Investors are aggressively purchasing shares of the company following the announcement that the company has entered a agreement with Janssen to co-develop...
-
Celgene Shares Higher On Positive Crohn's Patient Data
Monday, October 17, 2016 - 3:33pm | 358Read More...Celgene Corporation (NASDAQ: CELG) shares are up a modest 1.2 percent in Mondays session after the company’s United European Gastroenterology Week (UEGW) abstract revealed wide-spread activity for mongersen (GED-301) among Crohn’s patients. Although the full data will not be available...
-
AbbVie Says Risankizumab More Effective Than Placebo For Crohn's Disease Management
Tuesday, May 24, 2016 - 12:14pm | 379Read More...AbbVie Inc (NYSE: ABBV) disclosed that it presented a proof of concept, Phase II trial in Crohn's disease with investigatory biologic risankizumab, a compound from Boehringer Ingelheim research and recently licensed by the company. According to the company, Risankizumab was shown to be more...
-
Pfizer Receives FDA Approval For Cheaper Version Of Johnson & Johnson's Top Drug Remicade
Wednesday, April 6, 2016 - 10:45am | 327Read More...Pfizer Inc. (NYSE: PFE) announced after Tuesday's market close that the U.S. Food and Drug Administration approved INFLECTRA, the first and only biosimilar monoclonal antibody therapy, and only the second biosimilar to be approved in the US. INFLECTRA is a treatment indicated for reducing...
